Agree with your comment @Melody432 but the overall situation seems like a possible catch-22.
On one hand they have a product that appears to have multiple applications and therefore warrants multiple concurrent workstreams to explore the different applications. Given the lag time getting from idea > research > POC > testing > approval (and all the steps I've probably missed) I imagine it's only logical that a Company explore multiple applications concurrently.
On the other hand, I can understand why an investor might want AVH to focus on their core business and get it somewhere towards cashflow positivity? I suppose the team is big enough to handle the different workloads, but part of me would want them to absolutely nail the primary application before incurring all the time/costs/workload for the others.
Would be interested on your views on this, if you care to share.
Cheers
Ann: AVITA Medical Establishes Proof of Concept for Gene Therapy, page-13
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.02 |
Change
-0.060(1.95%) |
Mkt cap ! $212.6M | |||
| Open | High | Low | Value | Volume |
| $3.08 | $3.08 | $3.00 | $286.2K | 94.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1723 | $3.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.03 | 500 | 1 |
View Market Depth
| Last trade - 15.55pm 27/09/2024 (20 minute delay) ? |
| AVH (ASX) Chart |